2024
Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies
Morrison R, Singh J, Daly E, Fedgchin M, Ochs-Ross R, Karcher K, Lane R, Cooper K, Sanacora G, Maruff P, Drevets W. Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies. The International Journal Of Neuropsychopharmacology 2024, 27: pyae046. PMID: 39514643, PMCID: PMC11561565, DOI: 10.1093/ijnp/pyae046.Peer-Reviewed Original ResearchEsketamine nasal sprayTreatment-resistant depressionLong-term maintenance treatmentMADRS scoreOral antidepressantHopkins Verbal Learning Test-RevisedMaintenance treatmentCognitive test batteryEffects of esketamineGroup mean performanceFollow-up assessmentMild to moderate impairmentDepression severityTest-RevisedCogState batteryCognitive performancePsychomotor functionTest batteryCognitive testsCognitionEsketamineNasal sprayEffect sizeDepressionEffects of short-term
2023
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology 2023, 48: 1225-1233. PMID: 37173512, PMCID: PMC10267177, DOI: 10.1038/s41386-023-01577-5.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionEsketamine treatmentMontgomery-Åsberg Depression Rating Scale (MADRS) total scoreCommon treatment-emergent adverse eventsLong-term extension studyTreatment-emergent adverse eventsEsketamine nasal sprayMean cumulative durationLong-term tolerabilityNew safety signalsHealth-related qualityMaintenance of responseLong-term treatmentMajor depressive disorderLong-term safetyPhase 3Scale total scoreMaintenance phaseOral antidepressantsData cutoffAdverse eventsMaintenance treatmentSustained efficacyEligible participantsDepression ratings